119 related articles for article (PubMed ID: 15010837)
61. Simultaneous production of T helper-1-like cytokines and cytolytic activity by tumor-specific T cells in ovarian and breast cancer.
Goedegebuure PS; Douville CC; Doherty JM; Linehan DC; Lee KY; Ganguly EK; Eberlein TJ
Cell Immunol; 1997 Feb; 175(2):150-6. PubMed ID: 9023420
[TBL] [Abstract][Full Text] [Related]
62. The CD8+ T cell repertoire against Her-2/neu antigens in neu transgenic mice is of low avidity with antitumor activity.
Lustgarten J; Dominguez AL; Cuadros C
Eur J Immunol; 2004 Mar; 34(3):752-761. PubMed ID: 14991605
[TBL] [Abstract][Full Text] [Related]
63. In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein.
Disis ML; Smith JW; Murphy AE; Chen W; Cheever MA
Cancer Res; 1994 Feb; 54(4):1071-6. PubMed ID: 7508819
[TBL] [Abstract][Full Text] [Related]
64. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines.
Fisk B; Blevins TL; Wharton JT; Ioannides CG
J Exp Med; 1995 Jun; 181(6):2109-17. PubMed ID: 7539040
[TBL] [Abstract][Full Text] [Related]
65. Cellular immune response to human renal-cell carcinomas: definition of a common antigen recognized by HLA-A2-restricted cytotoxic T-lymphocyte (CTL) clones.
Bernhard H; Karbach J; Wölfel T; Busch P; Störkel S; Stöckle M; Wölfel C; Seliger B; Huber C; Meyer zum Büschenfelde KH
Int J Cancer; 1994 Dec; 59(6):837-42. PubMed ID: 7989126
[TBL] [Abstract][Full Text] [Related]
66. Analysis of MAGE-3 derived synthetic peptide as a human lung cancer antigen recognized by cytotoxic T lymphocytes.
Eifuku R; Takenoyama M; Yoshino I; Imahayashi S; So T; Yasuda M; Sugaya M; Yasumoto K
Int J Clin Oncol; 2001 Feb; 6(1):34-9. PubMed ID: 11706525
[TBL] [Abstract][Full Text] [Related]
67. Induction of antigen-specific CTL by recombinant HIV trans-activating fusion protein-pulsed human monocyte-derived dendritic cells.
Tanaka Y; Dowdy SF; Linehan DC; Eberlein TJ; Goedegebuure PS
J Immunol; 2003 Feb; 170(3):1291-8. PubMed ID: 12538688
[TBL] [Abstract][Full Text] [Related]
68. Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide.
Voutsas IF; Anastasopoulou EA; Tzonis P; Papamichail M; Perez SA; Baxevanis CN
J Immunother Cancer; 2016; 4():75. PubMed ID: 27891225
[TBL] [Abstract][Full Text] [Related]
69. Recognition by HLA-A2-restricted cytotoxic T lymphocytes of endogenously generated and exogenously provided synthetic peptide analogues of the influenza A virus matrix protein.
Sauma SY; Gammon MC; Bednarek MA; Cunningham B; Biddison WE; Hermes JD; Porter G; Tamhankar S; Hawkins JC; Bush BL
Hum Immunol; 1993 Aug; 37(4):252-8. PubMed ID: 8300410
[TBL] [Abstract][Full Text] [Related]
70. Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells.
Kawashima I; Tsai V; Southwood S; Takesako K; Sette A; Celis E
Cancer Res; 1999 Jan; 59(2):431-5. PubMed ID: 9927058
[TBL] [Abstract][Full Text] [Related]
71. Isolation of broadly reactive, tumor-specific, HLA Class-I restricted CTL from blood lymphocytes of a breast cancer patient.
Verdegaal EM; Huinink DB; Hoogstraten C; Marijnissen AK; Gorsira MB; Claas FH; Osanto S
Hum Immunol; 1999 Dec; 60(12):1195-206. PubMed ID: 10626733
[TBL] [Abstract][Full Text] [Related]
72. Generation of tumor-reactive CTL against the tumor-associated antigen HER2 using retrovirally transduced dendritic cells derived from CD34+ hemopoietic progenitor cells.
Meyer zum Büschenfelde C; Nicklisch N; Rose-John S; Peschel C; Bernhard H
J Immunol; 2000 Oct; 165(7):4133-40. PubMed ID: 11034426
[TBL] [Abstract][Full Text] [Related]
73. Ovarian cancer-associated lymphocyte recognition of folate binding protein peptides.
Peoples GE; Anderson BW; Fisk B; Kudelka AP; Wharton JT; Ioannides CG
Ann Surg Oncol; 1998 Dec; 5(8):743-50. PubMed ID: 9869522
[TBL] [Abstract][Full Text] [Related]
74. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice.
Motomura Y; Ikuta Y; Kuronuma T; Komori H; Ito M; Tsuchihara M; Tsunoda Y; Shirakawa H; Baba H; Nishimura Y; Kinoshita T; Nakatsura T
Int J Oncol; 2008 May; 32(5):985-90. PubMed ID: 18425324
[TBL] [Abstract][Full Text] [Related]
75. Changes in an HER-2 peptide upregulating HLA-A2 expression affect both conformational epitopes and CTL recognition: implications for optimization of antigen presentation and tumor-specific CTL induction.
Fisk B; Savary C; Hudson JM; O'Brian CA; Murray JL; Wharton JT; Ioannides CG
J Immunother Emphasis Tumor Immunol; 1995 Nov; 18(4):197-209. PubMed ID: 8680648
[TBL] [Abstract][Full Text] [Related]
76. Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity.
Keogh E; Fikes J; Southwood S; Celis E; Chesnut R; Sette A
J Immunol; 2001 Jul; 167(2):787-96. PubMed ID: 11441084
[TBL] [Abstract][Full Text] [Related]
77. Development of a cancer vaccine: peptides, proteins, and DNA.
Shiku H; Wang L; Ikuta Y; Okugawa T; Schmitt M; Gu X; Akiyoshi K; Sunamoto J; Nakamura H
Cancer Chemother Pharmacol; 2000; 46 Suppl():S77-82. PubMed ID: 10950153
[TBL] [Abstract][Full Text] [Related]
78. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.
Valmori D; Liénard D; Waanders G; Rimoldi D; Cerottini JC; Romero P
Cancer Res; 1997 Feb; 57(4):735-41. PubMed ID: 9044853
[TBL] [Abstract][Full Text] [Related]
79. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1 ) product.
Oka Y; Elisseeva OA; Tsuboi A; Ogawa H; Tamaki H; Li H; Oji Y; Kim EH; Soma T; Asada M; Ueda K; Maruya E; Saji H; Kishimoto T; Udaka K; Sugiyama H
Immunogenetics; 2000 Feb; 51(2):99-107. PubMed ID: 10663572
[TBL] [Abstract][Full Text] [Related]
80. The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes.
Vissers JL; De Vries IJ; Schreurs MW; Engelen LP; Oosterwijk E; Figdor CG; Adema GJ
Cancer Res; 1999 Nov; 59(21):5554-9. PubMed ID: 10554034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
